AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

This feature is a deep dive into the challenges of defining and treating Difficult-to-Treat Rheumatoid Arthritis (D2T-RA).

Patients receiving an immune checkpoint inhibitor for a neoplasm face an increased risk for rheumatoid arthritis, an observational study found.

A new Swedish study has, for the first time, shown a link between rheumatoid arthritis (RA) and cognitive decline in dementia ...

This article helps to dispel myths related to rheumatoid arthritis (RA) and raise awareness regarding it. From causes to ...

Think rheumatoid arthritis only affects the elderly? Or that exercise makes it worse? Time to bust these myths! We got in ...

A team of scientists from the University of Colorado has made an important discovery that could change how we understand and ...

Indian scientists have created an innovative self-actuating drug delivery system for Rheumatoid Arthritis, providing precise ...

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...

Clinical and Radiographic Outcomes of Four Different Treatment Strategies in Patients With Early Rheumatoid Arthritis (the Best Study): A Randomized, Controlled Trialfrom Arthritis & Rheumatism.

A positive association was found between osteoarthritis and overactive bladder (OAB), but rheumatoid arthritis and psoriatic ...

AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.